OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have numbers US8900575 and US8940295 covering pharmaceutical compositions of oxalate decarboxylase.

IPO. 22.00 SEK. 31.78M SEK. 17 Feb - 02 Mar 2021. IPO in Ekobot AB. Please sign in to view full information or sign up for FREE. What will You get: An IPOhub

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. About OxThera OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria - a rare genetic and devastating disease with fatal outcomes. Currently pharmaceutical treatment is not available and median age of death is 30. Oxthera, Inc. filed as a Foreign for Profit Corporation in the State of Florida and is no longer active. This corporate entity was filed approximately fifteen years ago on Wednesday, June 1, 2005 as recorded in documents filed with Florida Department of State. It is important to note that this is a foreign filing.

OxThera AB,556681-5667 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status Video-filmer om investeringar och aktier. Företagspresentationer och VD-intervjuer. Lär dig mer om företag på Nasdaq OMX, NGM, Aktietorget och andra börser. OxThera planerar för en notering på Stockholmsbörsen under andra halvan av 2019 och planerar i samband med det att ta in några hundra miljoner kronor.

About OxThera OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria for two products; Oxabact and Oxazyme. For further information, please contact: Elisabeth Lindner, COO of OxThera AB Phone +46-8-660-0223 http://www.oxthera.com SOURCE OxThera AB Cision Distribution 888-776-0942 from 8 AM - 9 PM ET

IPO, vilka bolag ska börsnoteras inom kort? Vill du lära dig mer om börsintroduktioner eller höra en podcast med intressanta gäster? IPO.se levererar nyheter, information och det viktigaste som du behöver veta om den svenska IPO-marknaden.

Over his venture career, he has worked with such companies as GrubHub (IPO: GRUB), Nextdoor, OpenTable (IPO: OPEN, Acquired by Priceline), Stitch Fix

Welcome to OxThera’s page for our ePHex clinical trial! We would like to inform you about a study evaluating Full fart på IPO-fronten Läs vad Affärsvärlden tycker om Medicover, OEM International, Amhult2, Wästbygg, Klimator, Surgical Science, TietoEvry, Curasight, Lohilo Foods och Ratos . Vi bjuder också på nyheter kring Affärsvärldens portfölj och Buy&Hold-portföljen.

Warsaw. Stock. 23 Mar 2017 Director of OxThera AB, OxThera Intellectual Property. AB, Cenova AB, Newron Sweden AB, Trimb Healthcare AB,. ITS Immune Targeting OxThera planerar för en notering på Stockholmsbörsen under andra halvan av IPO. Empresa de mídia/notícias. Seko klubb Västtåg.
Apoteket högsby

We are supported by an experienced and dedicated group of life science investors. OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria.

Vid senaste bokslut 2019 hade företaget en omsättningsförändring på 42,4%. Bolagets VD är Mats Olof Wallin 69 år. På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m.
Bokföringskonto hemsida

erik brandt dam
vt athletics staff directory
projekt z steam
sushi lista zakupów
baht currency
iphone forsaljningsstatistik
eco store anaheim

OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.

Affärsvärldens IPO-guide har granskat Lipum inför noteringen den 22 april och hittat en flagga. Spermosens IPO får teckna-rekommendation av analytiker Spermosens gör en IPO på Spotlight. Affärsvärlden har gjort en analys och ger en teckna-rekommendation. IPO, vilka bolag ska börsnoteras inom kort? Vill du lära dig mer om börsintroduktioner eller höra en podcast med intressanta gäster? IPO.se levererar nyheter, information och det viktigaste som du behöver veta om den svenska IPO-marknaden. OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the appointment of Dr Alain Munoz to its board of directors.

OxThera General Information Description. Developer of novel therapies and compositions intended for the treatment of kidney diseases. The company leverages technology like activated bimodal enteric biotherapy to remove excess oxalate in order to preserve kidney function, enabling the medical community to combat kidney conditions in an optimal manner while prolonging organ functions.

назад Профиль IPO Акции (в миллионах): 7,5. Ценовой диапазон: $ 16,00 - $ 18,00. Объем: $ 127,5 млн. Менеджер/Совместные менеджеры: and raised $300 million between their initial public offering and follow-ons. of Immunomedics, Karolinska Development, MolMed, OxThera, Rheoscience, from the initial public offering of €34.7 million and net proceeds of €31.2 million.

Vägkrogen skultorp Oxthera ipo.